BiotechTube

DS-1001b

Phase 2Active
1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

WHO Grade II Glioma

Conditions

WHO Grade II Glioma

Trial Timeline

Jul 8, 2020 → Aug 31, 2026

NCT ID
NCT04458272

About DS-1001b

DS-1001b is a phase 2 stage product being developed by Daiichi Sankyo for WHO Grade II Glioma. The current trial status is active. This product is registered under clinical trial identifier NCT04458272. Target conditions include WHO Grade II Glioma.

What happened to similar drugs?

0 of 7 similar drugs in WHO Grade II Glioma were approved

Approved (0) Terminated (1) Active (6)
🔄diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3
❌MEK162, MEK inhibitor; oral + Physician's choice chemotherapyPfizerPhase 3
🔄rituximabBiogenPhase 3
🔄Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3
🔄Remestemcel-LMesoblastPhase 3
🔄remestemcel-LMesoblastPhase 3
🔄avutometinib + Defactinib + Pegylated liposomal doxorubicin + Paclitaxel + Letrozole + AnastrozoleVerastem OncologyPhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04458272Phase 2Active
NCT03030066Phase 1Active

Competing Products

20 competing products in WHO Grade II Glioma

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-α-NETPerspective TherapeuticsPhase 1
27
azenosertibZentalis PharmaceuticalsPhase 2
32
Sepantronium BromideCothera BiosciencePhase 2
29
Rabeprazole SodiumEisaiPre-clinical
26
Binimetinib 15 MGOno PharmaceuticalPhase 2
42
Abemaciclib + LetrozoleEli LillyPhase 2
42
Pirtobrutinib + MosunetuzumabEli LillyPhase 2
42
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
21
DSP-0390Sumitomo PharmaPhase 1
33
Mirvetuximab soravtansine + CarboplatinAbbViePhase 2
39
Mirvetuximab SoravtansineAbbViePhase 2
42
Acalabrutinib + ObinutuzumabAstraZenecaPhase 2
42
Olaparib Pill + AZD6738AstraZenecaPhase 2
35
PembrolizumabMerckPhase 2
42
Efineptakin alfa + PembrolizumabMerckPhase 2
42
PembrolizumabMerckPhase 2
39
Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + DocetaxelMerckPhase 2
35
CilengitideMerckPhase 2
31
AvelumabMerckPhase 2
35
Human Papillomavirus vaccineMerckPhase 2
35